Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Stroke

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 75 articles:
HTML format
Text format



Single Articles


    November 2017
  1. RUSSO JJ, Goodman SG, Cantor WJ, Ko DT, et al
    Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis.
    Am Heart J. 2017;193:46-54.
    PubMed     Text format     Abstract available


    October 2017
  2. MOJOLI M, Gersh BJ, Barioli A, Masiero G, et al
    Impact of atrial fibrillation on outcomes of patients treated by transcatheter aortic valve implantation: A systematic review and meta-analysis.
    Am Heart J. 2017;192:64-75.
    PubMed     Text format     Abstract available


  3. VINEREANU D, Al-Khalidi HR, Rao MP, He W, et al
    Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF
    Am Heart J. 2017;192:38-47.
    PubMed     Text format     Abstract available


  4. DEHGHANI P, Lavoie A, Lavi S, Crawford JJ, et al
    Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Am Heart J. 2017;192:105-112.
    PubMed     Text format     Abstract available


    September 2017
  5. O'NEILL ES, Grande SW, Sherman A, Elwyn G, et al
    Availability of patient decision aids for stroke prevention in atrial fibrillation: A systematic review.
    Am Heart J. 2017;191:1-11.
    PubMed     Text format     Abstract available


    August 2017
  6. HIJAZI Z, Oldgren J, Andersson U, Connolly SJ, et al
    Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
    Am Heart J. 2017;190:94-103.
    PubMed     Text format     Abstract available


  7. BERNSTEIN RA, Kamel H, Granger CB, Kowal RC, et al
    Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial: Design and rationale.
    Am Heart J. 2017;190:19-24.
    PubMed     Text format     Abstract available


  8. KIRCHHOF P, Blank BF, Calvert M, Camm AJ, et al
    Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
    Am Heart J. 2017;190:12-18.
    PubMed     Text format     Abstract available


    July 2017
  9. HOLMES DR, Reddy VY, Buchbinder M, Stein K, et al
    The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial.
    Am Heart J. 2017;189:68-74.
    PubMed     Text format     Abstract available


  10. STEINBERG BA, Shrader P, Thomas L, Ansell J, et al
    Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Am Heart J. 2017;189:40-47.
    PubMed     Text format     Abstract available


    June 2017
  11. NEAL B, Tian M, Li N, Elliott P, et al
    Rationale, design, and baseline characteristics of the Salt Substitute and Stroke Study (SSaSS)-A large-scale cluster randomized controlled trial.
    Am Heart J. 2017;188:109-117.
    PubMed     Text format     Abstract available


    May 2017
  12. KARLSSON LO, Nilsson S, Charitakis E, Bang M, et al
    Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): Rationale and design of a cluster randomized trial in the primary care setting.
    Am Heart J. 2017;187:45-52.
    PubMed     Text format     Abstract available


  13. HESS CN, Clare RM, Neely ML, Tricoci P, et al
    Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.
    Am Heart J. 2017;187:194-203.
    PubMed     Text format     Abstract available


  14. DIEDERICHSEN SZ, Haugan KJ, Kober L, Hojberg S, et al
    Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial.
    Am Heart J. 2017;187:122-132.
    PubMed     Text format     Abstract available


  15. MENTZ RJ, Bethel MA, Gustavson S, Thompson VP, et al
    Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Am Heart J. 2017;187:1-9.
    PubMed     Text format     Abstract available


    April 2017
  16. DUCROCQ G, Schulte PJ, Budaj A, Cornel JH, et al
    Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
    Am Heart J. 2017;186:91-99.
    PubMed     Text format     Abstract available


    March 2017
  17. NAKANISHI K, Jin Z, Homma S, Elkind MS, et al
    Left ventricular mass-geometry and silent cerebrovascular disease: The Cardiovascular Abnormalities and Brain Lesions (CABL) study.
    Am Heart J. 2017;185:85-92.
    PubMed     Text format     Abstract available


  18. CHAMBERLAIN AM, Alonso A, Gersh BJ, Manemann SM, et al
    Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study.
    Am Heart J. 2017;185:74-84.
    PubMed     Text format     Abstract available


  19. LEE H, Koo BK, Park KW, Shin ES, et al
    A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary arte
    Am Heart J. 2017;185:17-25.
    PubMed     Text format     Abstract available


  20. HUFFMAN MD, Mohanan PP, Devarajan R, Baldridge AS, et al
    Acute coronary syndrome quality improvement in Kerala (ACS QUIK): Rationale and design for a cluster-randomized stepped-wedge trial.
    Am Heart J. 2017;185:154-160.
    PubMed     Text format     Abstract available


  21. WESTENBRINK BD, Alings M, Granger CB, Alexander JH, et al
    Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Am Heart J. 2017;185:140-149.
    PubMed     Text format     Abstract available


    February 2017
  22. ARMSTRONG PW, Zheng Y, Westerhout CM, Rosell-Ortiz F, et al
    Corrigendum to "Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial" [Am Heart J 169/6 (2015) 890-898].
    Am Heart J. 2017;184:157.
    PubMed     Text format    


  23. FANOLA CL, Mooney D, Cowan AJ, Ko D, et al
    Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants.
    Am Heart J. 2017;184:150-155.
    PubMed     Text format     Abstract available


  24. BERWANGER O, de Barros E Silva PG, Barbosa RR, Precoma DB, et al
    Atorvastatin for high-risk statin-naive patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial.
    Am Heart J. 2017;184:88-96.
    PubMed     Text format     Abstract available


  25. KHAN H, Jaffar N, Rauramaa R, Kurl S, et al
    Cardiorespiratory fitness and nonfatalcardiovascular events: A population-based follow-up study.
    Am Heart J. 2017;184:55-61.
    PubMed     Text format     Abstract available


    January 2017
  26. OSMANCIK P, Tousek P, Herman D, Neuzil P, et al
    Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study).
    Am Heart J. 2017;183:108-114.
    PubMed     Text format     Abstract available


    November 2016
  27. PROIETTI M, Laroche C, Drozd M, Vijgen J, et al
    Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
    Am Heart J. 2016;181:83-91.
    PubMed     Text format     Abstract available


  28. STEINBERG BA, Shrader P, Kim S, Thomas L, et al
    How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Am Heart J. 2016;181:145-152.
    PubMed     Text format     Abstract available


  29. VALENTINO M, Al Danaf J, Panakos A, Ragupathi L, et al
    Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
    Am Heart J. 2016;181:130-136.
    PubMed     Text format     Abstract available


  30. FERRI LA, Morici N, Grosseto D, Tortorella G, et al
    A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    Am Heart J. 2016;181:101-106.
    PubMed     Text format     Abstract available


    October 2016
  31. WINDECKER S, Tijssen J, Giustino G, Guimaraes AH, et al
    Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    Am Heart J. 2016;184:81-87.
    PubMed     Text format     Abstract available


  32. ALLEN JE, Knight S, McCubrey RO, Bair T, et al
    beta-blocker dosage and outcomes after acute coronary syndrome.
    Am Heart J. 2016;184:26-36.
    PubMed     Text format     Abstract available


  33. VAN DER MEERSCH H, De Bacquer D, De Vriese AS
    Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
    Am Heart J. 2016;184:37-46.
    PubMed     Text format     Abstract available


    September 2016
  34. BUCK J, Kaboli P, Gage BF, Cram P, et al
    Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
    Am Heart J. 2016;179:186-91.
    PubMed     Text format     Abstract available


  35. MARSO SP, McGuire DK, Zinman B, Poulter NR, et al
    Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.
    Am Heart J. 2016;179:175-83.
    PubMed     Text format     Abstract available


  36. TROXEL AB, Asch DA, Mehta SJ, Norton L, et al
    Rationale and design of a randomized trial of automated hovering for post-myocardial infarction patients: The HeartStrong program.
    Am Heart J. 2016;179:166-74.
    PubMed     Text format     Abstract available


  37. SHAH R, Hellkamp A, Lokhnygina Y, Becker RC, et al
    Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Am Heart J. 2016;179:77-86.
    PubMed     Text format     Abstract available


  38. DE WAHA A, Sandner S, von Scheidt M, Boening A, et al
    A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Inve
    Am Heart J. 2016;179:69-76.
    PubMed     Text format     Abstract available


  39. EZEKOWITZ MD, Pollack CV, Sanders P, Halperin JL, et al
    Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.
    Am Heart J. 2016;179:59-68.
    PubMed     Text format     Abstract available


    April 2016
  40. GOLWALA H, Jackson LR 2nd, Simon DN, Piccini JP, et al
    Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry.
    Am Heart J. 2016;174:29-36.
    PubMed     Text format     Abstract available


    February 2016
  41. EISEN A, Giugliano RP, Ruff CT, Nordio F, et al
    Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myoc
    Am Heart J. 2016;172:144-51.
    PubMed     Text format     Abstract available


  42. DIDIER R, Gaglia MA Jr, Koifman E, Kiramijyan S, et al
    Cerebrovascular accidents after percutaneous coronary interventions from 2002 to 2014: Incidence, outcomes, and associated variables.
    Am Heart J. 2016;172:80-7.
    PubMed     Text format     Abstract available


    January 2016
  43. JONES WS, Patel MR, Tsai TT, Shetterly SM, et al
    Response to Letter to the Editor regarding "Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization".
    Am Heart J. 2016;171:e7.
    PubMed     Text format    


  44. EYUBOGLU M
    Clinical outcomes in patients with lower extremity peripheral artery disease undergoing revascularization.
    Am Heart J. 2016;171:e5.
    PubMed     Text format    


    December 2015
  45. CHANDRASEKHAR J, Mastoris I, Baber U, Sartori S, et al
    Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry.
    Am Heart J. 2015;170:1234-42.
    PubMed     Text format     Abstract available


  46. LEE RJ, Lakkireddy D, Mittal S, Ellis C, et al
    Percutaneous alternative to the Maze procedure for the treatment of persistent or long-standing persistent atrial fibrillation (aMAZE trial): Rationale and design.
    Am Heart J. 2015;170:1184-94.
    PubMed     Text format     Abstract available


  47. AULIN J, Siegbahn A, Hijazi Z, Ezekowitz MD, et al
    Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
    Am Heart J. 2015;170:1151-60.
    PubMed     Text format     Abstract available


  48. MAGNUSON EA, Vilain K, Wang K, Li H, et al
    Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial.
    Am Heart J. 2015;170:1140-50.
    PubMed     Text format     Abstract available


    November 2015
  49. MELDUNI RM, Lee HC, Bailey KR, Miller FA Jr, et al
    Real-time physiologic biomarker for prediction of atrial fibrillation recurrence, stroke, and mortality after electrical cardioversion: A prospective observational study.
    Am Heart J. 2015;170:914-22.
    PubMed     Text format     Abstract available


    October 2015
  50. BANSILAL S, Bloomgarden Z, Halperin JL, Hellkamp AS, et al
    Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fi
    Am Heart J. 2015;170:675-682.
    PubMed     Text format     Abstract available


    September 2015
  51. LABAF A, Grzymala-Lubanski B, Sjalander A, Svensson PJ, et al
    Glomerular filtration rate and association to stroke, major bleeding, and death in patients with mechanical heart valve prosthesis.
    Am Heart J. 2015;170:559-65.
    PubMed     Text format     Abstract available


  52. PASTORI D, Pignatelli P, Farcomeni A, Cangemi R, et al
    Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation.
    Am Heart J. 2015;170:490-497.
    PubMed     Text format     Abstract available


    August 2015
  53. JONES WS, Patel MR, Tsai TT, Go AS, et al
    Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization.
    Am Heart J. 2015;170:400-408.
    PubMed     Text format     Abstract available


    July 2015
  54. DAMLUJI AA, Al-Damluji MS, Marzouka GR, Coffey JO, et al
    New-onset versus prior history of atrial fibrillation: Outcomes from the AFFIRM trial.
    Am Heart J. 2015;170:156-163.
    PubMed     Text format     Abstract available


  55. POKORNEY SD, Simon DN, Thomas L, Fonarow GC, et al
    Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
    Am Heart J. 2015;170:141-148.
    PubMed     Text format     Abstract available


  56. CRESSMAN AM, Macdonald EM, Yao Z, Austin PC, et al
    Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: A population-based study.
    Am Heart J. 2015;170:133-140.
    PubMed     Text format     Abstract available


  57. OKRAINEC K, Bell CM, Hollands S, Booth GL, et al
    Risk of cardiovascular events and mortality among a population-based cohort of immigrants and long-term residents with diabetes: Are all immigrants healthier and if so, for how long?
    Am Heart J. 2015;170:123-32.
    PubMed     Text format     Abstract available


  58. ERDMANN E, Califf R, Gerstein HC, Malmberg K, et al
    Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
    Am Heart J. 2015;170:117-22.
    PubMed     Text format     Abstract available


  59. LIAKOPOULOS OJ, Kuhn EW, Hellmich M, Kuhr K, et al
    Statin Recapture Therapy before Coronary Artery Bypass Grafting Trial: Rationale and study design of a multicenter, randomized, double-blinded controlled clinical trial.
    Am Heart J. 2015;170:46-54.
    PubMed     Text format     Abstract available


  60. XIAN Y, O'Brien EC, Fonarow GC, Olson DM, et al
    Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care.
    Am Heart J. 2015;170:36-45.
    PubMed     Text format     Abstract available


    June 2015
  61. SUGIOKA K, Takagi M, Sakamoto S, Fujita S, et al
    Predictors of silent brain infarction on magnetic resonance imaging in patients with nonvalvular atrial fibrillation: A transesophageal echocardiographic study.
    Am Heart J. 2015;169:783-90.
    PubMed     Text format     Abstract available


  62. WANG Y, Li Z, Xian Y, Zhao X, et al
    Rationale and design of a cluster-randomized multifaceted intervention trial to improve stroke care quality in China: The GOLDEN BRIDGE-Acute Ischemic Stroke.
    Am Heart J. 2015;169:767-774.
    PubMed     Text format     Abstract available


  63. SARICH TC, Seltzer JH, Berkowitz SD, Costin' J, et al
    Novel oral anticoagulants and reversal agents: Considerations for clinical development.
    Am Heart J. 2015;169:751-7.
    PubMed     Text format     Abstract available


    May 2015
  64. LIP GY, Merino J, Ezekowitz M, Ellenbogen K, et al
    A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Am Heart J. 2015;169:597-604.
    PubMed     Text format     Abstract available


    March 2015
  65. MELGAARD L, Gorst-Rasmussen A, Lip GY, Rasmussen LH, et al
    Female sex is associated with a lower risk of stroke in patients with heart failure.
    Am Heart J. 2015;169:396-403.
    PubMed     Text format     Abstract available


  66. LI S, Wu Y, Du X, Li X, et al
    Rational and design of a stepped-wedge cluster randomized trial evaluating quality improvement initiative for reducing cardiovascular events among patients with acute coronary syndromes in resource-constrained hospitals in China.
    Am Heart J. 2015;169:349-55.
    PubMed     Text format     Abstract available


    January 2015
  67. STAFINSKI T, Menon D, Nardelli A, Bakal J, et al
    Incorporating patient preferences into clinical trial design: results of the opinions of patients on treatment implications of new studies (OPTIONS) project.
    Am Heart J. 2015;169:122-31.
    PubMed     Text format     Abstract available


  68. WANG Y, Lichtman JH, Dharmarajan K, Masoudi FA, et al
    National trends in stroke after acute myocardial infarction among Medicare patients in the United States: 1999 to 2010.
    Am Heart J. 2015;169:78-85.
    PubMed     Text format     Abstract available


  69. NAVAR-BOGGAN AM, Rymer JA, Piccini JP, Shatila W, et al
    Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke.
    Am Heart J. 2015;169:39-44.
    PubMed     Text format     Abstract available


  70. GRANGER CB, Lopes RD, Hanna M, Ansell J, et al
    Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Am Heart J. 2015;169:25-30.
    PubMed     Text format     Abstract available


  71. CAIRNS JA, Weitz JI
    Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
    Am Heart J. 2015;169:1-3.
    PubMed     Text format    


    December 2014
  72. TRICOCI P, Lokhnygina Y, Huang Z, Van de Werf F, et al
    Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial.
    Am Heart J. 2014;168:869-877.
    PubMed     Text format     Abstract available


  73. GUERRA E, Ndrepepa G, Schulz S, Byrne R, et al
    Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention.
    Am Heart J. 2014;168:862-868.
    PubMed     Text format     Abstract available


  74. VALGIMIGLI M
    Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program.
    Am Heart J. 2014;168:838-45.
    PubMed     Text format     Abstract available


  75. VISCOLI CM, Brass LM, Carolei A, Conwit R, et al
    Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
    Am Heart J. 2014;168:823-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Stroke is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: